Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2022

Open Access 01-12-2022 | Fibromyalgia | Study protocol

A drug free solution for improving the quality of life of fibromyalgia patients (Fibrepik): study protocol of a multicenter, randomized, controlled effectiveness trial

Authors: Emilie Chipon, Jean-Luc Bosson, Laure Minier, Anne Dumolard, Antoine Vilotitch, David Crouzier, Caroline Maindet

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Fibromyalgia is a form of chronic widespread pain that is defined as a syndrome of chronic symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, cognitive impairment, and numerous somatic complaints. To date, there is no specific drug treatment for fibromyalgia but only symptomatic treatments. A drug free solution based on a wristband that emits millimeter waves associated with a therapeutic coaching program was developed. The application of millimeter waves on an innervated area has been described to have a neuromodulating effect, due to endorphin release stimulation and parasympathetic activation. Coaching is carried out to improve the patient’s adherence and to increase compliance and effectiveness of the treatment. Regular use of this solution by fibromyalgia patients is expected to improve sleep quality, reduce anxiety and pain levels, and, at the end, increase the quality of life.

Methods

This trial is performed over 8 French inclusion centers for a total of 170 patients. The effectiveness of the solution is evaluated according to the primary objective, the improvement of the quality of life measured through the dedicated Fibromyalgia Impact Questionnaire after 3 months. Patients are randomized in two groups, Immediate or Delayed. The Immediate group has access to the solution just after randomization in addition to standard care, while Delayed has access to the standard of care and waits for 3 months to have the solution. The purpose of this methodology is to limit deception bias and facilitate inclusion. The solution consists in using the device for three sessions of 30 min per day and four coaching sessions spread over the first 2 months of wristband usage.

Discussion

The objective is to confirm the effect of the integrative approach based on endorphin stimulation and a therapeutic coaching program in nociplastic pain and specifically for the patient suffering from fibromyalgia. If the effectiveness of the solution is demonstrated, we will be able to respond to the demand of fibromyalgia patients for access to an effective non-medicinal treatment to improve their quality of life.

Trial registration

Appendix
Available only for authorised users
Literature
1.
Benlidayi IC. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781–91.CrossRef
2.
Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8(1):1–11.CrossRef
3.
Clauw DJ. Fibromyalgia and related conditions. In: Mayo Clinic Proceedings Elsevier; 2015. p. 680–92.
4.
Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73(1):114–20.CrossRef
5.
Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–28.CrossRef
6.
Radzievsky AA, Rojavin MA, Cowan A, Alekseev SI, Radzievsky AA, Ziskin MC. Peripheral neural system involvement in hypoalgesic effect of electromagnetic millimeter waves. Life Sci. 2001;68(10):1143–51.CrossRef
7.
Radzievsky AA, Gordiienko OV, Alekseev S, Szabo I, Cowan A, Ziskin MC. Electromagnetic millimeter wave induced hypoalgesia: Frequency dependence and involvement of endogenous opioids. Bioelectromagnetics. 2008;29(4):284–95.CrossRef
8.
Rojavin A, MC Ziskin M. Electromagnetic millimeter waves increase the duration of anaesthesia caused by ketamine and chloral hydrate in mice. Int J Radiat Biol. 1997;72(4):475–80.CrossRef
9.
Radzievsky AA, Rojavin MA, Cowan A, Alekseev SI, Ziskin MC. Hypoalgesic effect of millimeter waves in mice: Dependence on the site of exposure. Life Sci. 2000;66(21):2101–11.CrossRef
10.
Radzievsky A, Gordiienko O, Cowan A, Alekseev SI, Ziskin MC. Millimeter-wave-induced hypoalgesia in mice: dependence on type of experimental pain. IEEE Transact Plasma Sci. 2004;32(4):1634–43.CrossRef
11.
Rojavin A, Radzievsky AA, Cowan A, Ziskin MC. Pain relief caused by millimeter waves in mice: results of cold water tail flick tests. Int J Radiat Biol. 2000;76(4):575–9.CrossRef
12.
Radzievsky AA, Rojavin MA, Cowan A, Ziskin MC. Suppression of pain sensation caused by millimeter waves: a double-blinded, cross-over, prospective human volunteer study. Anesth Analg. 1999;88(4):836–40.CrossRef
13.
Usichenko TI, Herget HF. Treatment of chronic pain with millimetre wave therapy (MWT) in patients with diffuse connective tissue diseases: a pilot case series study. Eur J Pain. 2003;7(3):289–94.CrossRef
14.
Usichenko TI, Ivashkivsky OI, Gizhko VV. Treatment of rheumatoid arthritis with electromagnetic millimeter waves applied to acupuncture points-a randomized double blind clinical study. Acupuncture Electro-Ther Res. 2003;28(1–2):11–8.CrossRef
15.
Usichenko TI, Edinger H, Gizhko VV, Lehmann C, Wendt M, Feyerherd F. Low-intensity electromagnetic millimeter waves for pain therapy. Evid Based Complement Alternat Med. 2006;3(2):201–7.CrossRef
16.
Moazezi Z, Hojjati SMM, Ayrapetyan S. Low Intensity Millimeter Wave as a Potential Tool in Treatment of Diabetic Sensorymotor Polyneuropathy. Int Dental Med Disord. 2008;1(1).
17.
Egawa M, Yoshimatsu H, Bray GA. Effect of beta-endorphin on sympathetic nerve activity to interscapular brown adipose tissue. Am J Phys Regul Integr Comp Phys. 1993;264(1):R109–15.
18.
Haddad GG, Jeng HJ, Lai TL. Effect of endorphins on heart rate and blood pressure in adult dogs. Am J Phys Heart Circ Phys. 1986;250(5):H796–805.
19.
Holaday JW. Cardiovascular Effects of Endogenous Opiate Systems. Annu Rev Pharmacol Toxicol. 1983;23(1):541.CrossRef
20.
Wong TM, Shan J. Modulation of sympathetic actions on the heart by opioid receptor stimulation. J Biomed Sci. 2001;8(4):299–306.CrossRef
21.
Drolet G, Dumont IC, Gosselin I, Kinkead R, Laforest S, Troti’Ier O. Role of endogenous opioid system in the regulation of the stress response. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25(4):729–41.CrossRef
22.
23.
Moldofsky H. The significance of the sleeping–waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine. 2008;75(4):397–402.CrossRef
24.
Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain. 1996;68(2):363–8.CrossRef
25.
Ashburn MA, Staats PS. Management of chronic pain. Lancet. 1999;353(9167):1865–9.CrossRef
26.
Versluis A, Verkuil B, Spinhoven P, van der Ploeg MM, Brosschot JF. Changing Mental Health and Positive Psychological Well-Being Using Ecological Momentary Interventions: A Systematic Review and Meta-analysis. J Med Internet Res. 2016;18(6):e5642.CrossRef
27.
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–29.CrossRef
28.
Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2):92–8.CrossRef
29.
Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire. J Rheumatol. 2009;36(6):1304–11.CrossRef
30.
Perrot S, Dumont D, Guillemin F, Pouchot J, Coste J. Research FG for Q of L. Quality of life in women with fibromyalgia syndrome: validation of the QIF, the French version of the fibromyalgia impact questionnaire. J Rheumatol. 2003;30(5):1054–9.PubMed
31.
Buysse DJ, Reynolds CF III, Monk TH, Berman SR, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRef
32.
Lepine JP, Godchau M, Brun P. Anxiety and depression in inpatients. Lancet. 1985;2(8469–70):1425–6.CrossRef
33.
Smets EMA, Garssen B, Bonke B, De Haes JCJM. The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25.CrossRef
34.
Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef
35.
Cleland CL, Hunter RF, Kee F, Cupples ME, Sallis JF, Tully MA. Validity of the Global Physical Activity Questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. BMC Public Health. 2014;14(1):1255.CrossRef
36.
Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1(1):e000146.CrossRef
37.
Lallemand C, Koenig V. How Could an Intranet be Like a Friend to Me? Why Standardized UX Scales Don’t Always Fit. In: Proceedings of the European Conference on Cognitive Ergonomics 2017. New York: Association for Computing Machinery; 2017. p. 9–16. https://​doi.​org/​10.​1145/​3121283.​3121288. (ECCE 2017). [cited 2022 Jan 28].CrossRef
38.
Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23(Suppl. 39):S154–62.PubMed
39.
Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098–110.CrossRef
Metadata
Title
A drug free solution for improving the quality of life of fibromyalgia patients (Fibrepik): study protocol of a multicenter, randomized, controlled effectiveness trial
Authors
Emilie Chipon
Jean-Luc Bosson
Laure Minier
Anne Dumolard
Antoine Vilotitch
David Crouzier
Caroline Maindet
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06693-z

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue

Research

Association between blood glucose levels and Glasgow Outcome Score in patients with traumatic brain injury: secondary analysis of a randomized trial

Study protocol

Effectiveness of lumbar stabilization exercise with real-time ultrasound imaging biofeedback on lumbar multifidus muscle cross-sectional area in individuals with non-specific chronic low back pain: a study protocol for a randomized controlled trial

Study protocol

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial

Study protocol

Parasternal After Cardiac Surgery (PACS): a prospective, randomised, double-blinded, placebo-controlled trial study protocol for evaluating a continuous bilateral parasternal block with lidocaine after open cardiac surgery through sternotomy

Study protocol

Reducing HIV-related stigma among young people attending school in Northern Uganda: study protocol for a participatory arts-based population health intervention and stepped-wedge cluster-randomized trial

Study protocol

Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)